TY - JOUR
T1 - Improvement of Vestibular Neuritis in a Patient with Psoriatic Arthritis following Ixekizumab Administration
AU - Ershadi, Sherry
AU - Amara, Shivkar
AU - Lebwohl, Mark
N1 - Publisher Copyright:
© 2024 THE AUTHORS. Published in collaboration with Dermsquared.
PY - 2024/7
Y1 - 2024/7
N2 - Psoriatic arthritis (PsA) is a chronic inflammatory condition commonly affecting peripheral joints and the skin. Recent studies have shown an association between PsA and vestibulocochlear dysfunction. Here, we present the case of a 43 year-old male with a history of controlled psoriasis (Pso) and PsA who presented with sudden-onset severe vertigo, nausea, and vomiting. Diagnostic evaluation ruled out a central etiology, leading to a diagnosis of vestibular neuritis of unknown origin. Despite minimal improvement with conventional medications, the patient experienced significant relief from vertigo symptoms following treatment with ixekizumab, an IL-17 inhibitor used to manage his PsA and Pso. This case highlights a potential therapeutic effect of biological agents on vestibular dysfunction associated with PsA. Future research in this area may provide insights into novel treatment strategies for vestibular symptoms in patients with PsA.
AB - Psoriatic arthritis (PsA) is a chronic inflammatory condition commonly affecting peripheral joints and the skin. Recent studies have shown an association between PsA and vestibulocochlear dysfunction. Here, we present the case of a 43 year-old male with a history of controlled psoriasis (Pso) and PsA who presented with sudden-onset severe vertigo, nausea, and vomiting. Diagnostic evaluation ruled out a central etiology, leading to a diagnosis of vestibular neuritis of unknown origin. Despite minimal improvement with conventional medications, the patient experienced significant relief from vertigo symptoms following treatment with ixekizumab, an IL-17 inhibitor used to manage his PsA and Pso. This case highlights a potential therapeutic effect of biological agents on vestibular dysfunction associated with PsA. Future research in this area may provide insights into novel treatment strategies for vestibular symptoms in patients with PsA.
UR - https://www.scopus.com/pages/publications/85200558052
U2 - 10.25251/skin.8.4.10
DO - 10.25251/skin.8.4.10
M3 - Letter
AN - SCOPUS:85200558052
SN - 2574-1624
VL - 8
SP - 1708
EP - 1710
JO - SKIN: Journal of Cutaneous Medicine
JF - SKIN: Journal of Cutaneous Medicine
IS - 4
ER -